Access, Affordability, and Sustainability: Barriers to High-Quality Care in a High-Income Country

Toms Vengaloor Thomas; Aju Mathew

doi:10.1055/s-0042-1748798

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(03): 285-288
DOI: 10.1055/s-0042-1748798

Perspective

Access, Affordability, and Sustainability: Barriers to High-Quality Care in a High-Income Country

Toms Vengaloor Thomas

¹Department of Radiation Oncology, University of Mississippi, Mississippi, United States

,

Aju Mathew

²Department of Oncology, Malankara Orthodox Syrian Church Medical College Kolenchery, Kochi, Kerala, India

References
1 Fundytus A, Sengar M, Lombe D. et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol 2021; 22 (10) 1367-1377
2 American Society of Clinical Oncology. The State of Cancer Care in America, 2017: a report by the American Society of Clinical Oncology. J Oncol Pract 2017; 13 (04) e353-e394
3 Gordon LG, Merollini KMD, Lowe A, Chan RJ. A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay. Patient 2017; 10 (03) 295-309
4 Zafar SY, Peppercorn JM, Schrag D. et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013; 18 (04) 381-390
5 Royce TJ, Schenkel C, Kirkwood K, Levit L, Levit K, Kircher S. Impact of pharmacy benefit managers on oncology practices and patients. JCO Oncol Pract 2020; 16 (05) 276-284
6 Beyer KMM, Zhou Y, Laud PW. et al. Mortgage lending bias and breast cancer survival among older women in the United States. J Clin Oncol 2021; 39 (25) 2749-2757
7 Mahal BA, Chen YW, Muralidhar V. et al. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol 2017; 28 (05) 1098-1104
8 Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol 2004; 171 (04) 1504-1507
9 Yoo W, Kim S, Huh WK. et al. Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One 2017; 12 (02) e0172548
10 Albert A, Giri S, Kanakamedala M. et al. Racial disparities in tumor features and outcomes of patients with squamous cell carcinoma of the tonsil. Laryngoscope 2019; 129 (03) 643-654
11 Goodwin JS, Freeman JL, Mahnken JD, Freeman DH, Nattinger AB. Geographic variations in breast cancer survival among older women: implications for quality of breast cancer care. J Gerontol A Biol Sci Med Sci 2002; 57 (06) M401-M406
12 Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 2005; 14 (03) 590-595
13 Lin Y, Wimberly MC. Geographic variations of colorectal and breast cancer late-stage diagnosis and the effects of neighborhood-level factors. J Rural Health 2017; 33 (02) 146-157
14 Boby JM, Rajappa S, Mathew A. Financial toxicity in cancer care in India: a systematic review. Lancet Oncol 2021; 22 (12) e541-e549
15 Zafar SY. Financial toxicity of cancer care: it's time to intervene. J Natl Cancer Inst 2015; 108 (05) djv370
16 Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol 2011; 29 (20) 2821-2826
17 Davidoff AJ, Erten M, Shaffer T. et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 2013; 119 (06) 1257-1265
18 Ramsey S, Blough D, Kirchhoff A. et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 2013; 32 (06) 1143-1152
19 Hanratty B, Holland P, Jacoby A, Whitehead M. Financial stress and strain associated with terminal cancer–a review of the evidence. Palliat Med 2007; 21 (07) 595-607
20 Fenn KM, Evans SB, McCorkle R. et al. Impact of financial burden of cancer on survivors' quality of life. J Oncol Pract 2014; 10 (05) 332-338
21 Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014; 32 (04) 306-311
22 Patel MS, Reed DA, Loertscher L, McDonald FS, Arora VM. Teaching residents to provide cost-conscious care: a national survey of residency program directors. JAMA Intern Med 2014; 174 (03) 470-472
23 Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev 2020; 29 (07) 1304-1312
24 Clarke JL, Laskowski RJ, Coons C. et al. Proceedings of the Christiana Care Health System Value Institute Value Symposium. Am J Med Qual 2012; 27 (6, Suppl): 3S-20S
25 Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102 (09) 605-613
26 Lyu H, Xu T, Brotman D. et al. Overtreatment in the United States. PLoS One 2017; 12 (09) e0181970
27 Schnipper LE, Smith TJ, Raghavan D. et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012; 30 (14) 1715-1724
28 Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol 2017; 14 (06) 381-390
29 Santos PMG, Mathis NJ, Lapen K. et al. Assessment of Guideline-Nonconcordant Radiotherapy in Medicare Beneficiaries With Metastatic Cancer Near the End of Life, 2015- 2017. JAMA Health Forum 2022; e214468-e214468
30 Woolhandler S, Himmelstein DU. Single-payer reform: the only way to fulfill the president's pledge of more coverage, better benefits, and lower costs. Ann Intern Med 2017; 166 (08) 587-588
31 Allan GM, Lexchin J. Physician awareness of diagnostic and nondrug therapeutic costs: a systematic review. Int J Technol Assess Health Care 2008; 24 (02) 158-165
32 Feldman LS, Shihab HM, Thiemann D. et al. Impact of providing fee data on laboratory test ordering: a controlled clinical trial. JAMA Intern Med 2013; 173 (10) 903-908
33 Institute of Medicine. 2013. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington, DC: The National Academies Press. https://doi.org/10.17226/13444.
34 Hahn C, Kavanagh B, Bhatnagar A. et al. Choosing wisely: the American Society for Radiation Oncology's top 5 list. Pract Radiat Oncol 2014; 4 (06) 349-355
35 Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 2018; 68 (02) 153-165
36 Sachs R. Administration finalizes most-favored nation drug pricing rule at the last minute. Health Aff Blog 2020
37 Butcher L. Price transparency. Hosp Health Netw. Jun 2014;88(6):32–7, 1.
38 Nair R, Radhakrishnan VS, Mallath MK. Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India. Lancet Haematol 2021; 8 (08) e548-e549